GlobeNewsWire
07 Oct 2025, 11:00 UTC · 49w ago
Verdict
Headline takes no side. We score AKRO +0.40 across four claims — moderately bullish.
+0.40moderately bullish
More positive than 61% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Akero Therapeutics will present 96-week Phase 2b SYMMETRY data showing efruxifermin (EFX) was associated with improvements in non-invasive tests for fibrosis regression in patients with compensated cirrhosis.
So whatPositive efficacy data in a high-need patient population (cirrhosis) is a primary catalyst for clinical-stage biotech valuations.
More positive than 91% of claims this week
Akero will present results from the Phase 2b SYMMETRY trial indicating EFX improved markers of portal hypertension based on Baveno VII criteria.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 84% of claims this week
The company will present AI-powered digital histology analysis from the 96-week Phase 2b HARMONY study regarding liver microarchitecture changes in pre-cirrhotic MASH patients.
More positive than 63% of claims this week
Akero's lead candidate efruxifermin is currently being evaluated in three ongoing Phase 3 clinical studies (SYNCHRONY Histology, Outcomes, and Real-World).
More positive than 51% of claims this week
Which stocks this story touches
More positive than 61% of ticker scores this week
The company is presenting new clinical data from Phase 2b studies, indicating progress in the development of its lead product candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
3d ago
+18.7%
Price agrees with the score
$54.65 vs $46.04 close before publication (Oct 6) · not market-adjusted
AKRO chart →
